Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients( ♦ ♦ Grant Support: This study was funded by Roche. The sponsor contributed to study design as well as data collection, analysis, and interpretation with input from the investigators. Writing support was provided by Blair Jarvis of Health Interactions and funded by Hoffman La-Roche Ltd. ClinicalTrials.gov Identifier: NCT00517439 )
Titel:
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients( ♦ ♦ Grant Support: This study was funded by Roche. The sponsor contributed to study design as well as data collection, analysis, and interpretation with input from the investigators. Writing support was provided by Blair Jarvis of Health Interactions and funded by Hoffman La-Roche Ltd. ClinicalTrials.gov Identifier: NCT00517439 )
Auteur:
Nelson, David R. Zeuzem, Stefan Andreone, Pietro Ferenci, Peter Herring, Robert Jensen, Donald M. Marcellin, Patrick Pockros, Paul J. Rodríguez-Torres, Maribel Rossaro, Lorenzo Rustgi, Vinod K. Sepe, Thomas Sulkowski, Mark Thomason, Isaac R. Yoshida, Eric M. Chan, Anna Hill, George